加拿大Resverlogix  
Resverlogix Corp. (TSX: RVX) 是一家心血管疾病临床研究公司，公司拥有能够调节蛋白质形成的表观遗传学平台技术。Resverlogix 正在开发 RVX-208——用于治疗动脉粥样硬化的同类首个小分子。RVX-208 是首个正在进行临床试验的 BET 溴区结构域抑制剂。出自 Resverlogix 表观遗传学药物发现平台的新复合制剂通过抑制 BET 溴区结构域而发挥作用，并有希望用来治疗癌症、自身免疫性疾病和神经退行性疾病等多种病症。Resverlogix 的普通股在多伦多证券交易所交易 (TSX: RVX)。

Resverlogix Corp. is a publicly traded biotechnology company (TSX:RVX) engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases.

Our Business Model is to seek strategic opportunities through early alliance partnerships that are best suited to bring our technology platforms to successful commercialization. We are committed to good corporate governance and protection of shareholder value.